Healthcare / BiotechnologyASX
$0.05
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-433608.00 · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$19M
P/E
4.6x
↓EV/EBITDA
N/A
•ROE
43.5%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-0.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $4.0M · FCF $-499981.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | — | — | $94368.00 | $13333.00 |
| Net Income | $4.0M | $4.0M | $1.1M | $-10.2M | $-576076.00 | — |
| EBITDA | $-675482.00 | $-675482.00 | $-675882.00 | $-561232.00 | $-576712.00 | — |
| EPS | 0.01 | 0.01 | 0.00 | -0.04 | -0.00 | — |
| Gross Margin | — | — | — | — | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | -611.1% | — |
| Net Margin | — | — | — | — | -610.5% | — |
| Balance Sheet | ||||||
| Current Ratio | 6.85 | 6.85 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-499981.00 | $-499981.00 | $-404757.00 | $-433608.00 | $-392911.00 | — |
| Returns | ||||||
| ROE | 43.5% | 43.5% | 21.3% | -365.8% | -4.5% | — |
| Valuation | ||||||
| P/E | 4.58 | 4.58 | 11.52 | — | — | — |
| P/B | 1.99 | 1.99 | 2.43 | 2.13 | 0.88 | — |
| Growth & Yield | ||||||
| Revenue Growth | — | — | — | — | 607.8% | — |
| EPS Growth | 257.6% | 257.6% | 109.1% | -1705.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-25.9%
EPS terminal req.
$0.00
Spread vs growth
283.5%
5Y implied EPS CAGR
-13.2%
EPS terminal req.
$0.01
Spread vs growth
270.8%
10Y implied EPS CAGR
-2.3%
EPS terminal req.
$0.01
Spread vs growth
259.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.8%
Start / end P/E
15.8x → 4.6x
EPS bridge
0.00 → 0.01
Residual
-182.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.